CRBU Caribou Bio Company Assets

CRBU (Caribou Bio) - company brandmark

The price history of Caribou Biosciences (CRBU) reflects asset dynamics with a volume of 181.82. The business is vulnerable to logistics disruptions and external restrictions during drug testing. The company's competitive advantage is based on an exclusive rights system for innovative DNA editing. Meanwhile, project development depends not on market cycles, but on the outcomes of medical research and the availability of investment.

CRBU - Caribou Biosciences, Inc. Company Total Assets over the range 07/04/2022 - 11/01/2026

Analytical breakdowns and data insights for company Caribou Bio (CRBU)

- market value and analyst target forecast:
Stock Price cariboubio.com|CRBU - Price Target Chart
- market capitalization data:
Market Value Caribou Biosciences, Inc|CRBU - Total Company Value
- balance sheet equity data:
Equity per Share Caribou Biosciences|CRBU - Book Capitalization|Market Cap to Net Assets Ratio cariboubio.com|CRBU - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Caribou Biosciences|CRBU - Long-Term Debt to Equity|Short-Term Debt to Equity Caribou Biosciences, Inc|CRBU - Company Debts|Debts to Book Value Caribou Biosciences, Inc|CRBU - Company Long-Term Debts|Short-Term Indebtedness Caribou Biosciences|Immediate Liquidity cariboubio.com
- earnings and market ratios statistics:
CRBU - Net Income
Basic company analysis:CRBU cariboubio.com
Signature product of Caribou Biosciences, Inc

The indicator's dynamics depend directly on the efficiency of profit generation per unit of resources. This metric reflects the total value of all controlled assets, calculated inversely through return on assets (ROA). For Caribou Biosciences (CRBU), the growth of this value confirms the expansion of the foundation for developing ultra-precise CAR-T systems and chRDNA technology. An analysis of the structure of total capital and liabilities allows for an assessment of the company's fundamental stability.

Direct competitors

legendbiotech.com (LEGN) - Company Total Assets|Aggregate Company Assets Sana Biotechnology, Inc.|Company Assets Autolus Therapeutics PLC AUTL|Aggregate Company Assets Allogene Therapeutics Inc (ALLO)|Selecta Biosciences Inc. - Total Business Assets|Company Total Assets CLLS (Cellectis)|TIL - Cumulative Company Assets|GNTA - Aggregate Company Assets|Company Assets Century Therapeutics|jaspertherapeutics.com (JSPR) - Aggregate Company Assets|SNTI (Senti Biosciences) - Aggregate Company Assets|Aggregate Company Assets Adaptimmune Therapeutics plc|Company Assets CERo Therapeutics Holdings Inc. CERO|Company Total Assets TCRT|achillestx.com (ACHL) - Company Balance Sheet Assets|Cargo Therapeutics - Cumulative Company Assets|Poseida Corp (PSTX) - Company Assets|TSVT: Cumulative Company Assets|Aggregate Asset Value GRCL (gracellbio.com)